CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Data Access
Data Quality
Regulation by Litigation
Regulation by Appropriation
Special Projects
CRE Watch List
OMB Papers
Abstracts and Reviews
Regulatory Review
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Consumer Response Service
Site Search

Enter keyword(s) to search

®: CRE Regulatory Action of the Week

FDA Amends Biological Product Definition and Defines the Statutory Term Protein
The U.S. Food and Drug Administration has issued a final rule amending its regulation that defines biological product. This final rule incorporates changes made by the Biologics Price Competition and Innovation Act of 2009 and the Further Consolidated Appropriations Act of 2020. It also provide FDA interpretation of the statutory term protein. Under this final rule, the term protein means any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. This final rule is intended to clarify the statutory framework under which such products are regulated. This rule is effective March 23, 2020. Click here for more information and relevant links.

REGweek Archive